Ovarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer ...
(Left) Synergistic cell death observed when combining BRAF inhibitors with polyamine biosynthesis inhibitors or mitochondrial activity inhibitors. (Right) Confirmation of synergistic anticancer ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase ...
Ovarian cancer is one of the most common malignancies in women worldwide. Unlike breast cancer, ovarian cancer lacks early diagnostic markers and does not show noticeable symptoms until cancer ...
Researchers have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results